Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need

Information

  • Research Project
  • 10255421
  • ApplicationId
    10255421
  • Core Project Number
    R44TR001912
  • Full Project Number
    3R44TR001912-03S3
  • Serial Number
    001912
  • FOA Number
    PA-18-591
  • Sub Project Id
  • Project Start Date
    11/1/2020 - 4 years ago
  • Project End Date
    3/1/2021 - 4 years ago
  • Program Officer Name
    PORTILLA, LILLIANNE M
  • Budget Start Date
    11/1/2020 - 4 years ago
  • Budget End Date
    3/1/2021 - 4 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
    S3
  • Award Notice Date
    10/31/2020 - 4 years ago
Organizations

Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need

PROJECT SUMMARY GoDx, Inc. has been developing a prototype multiplexed paper strip device for the detection of the DNA and RNA of gastrointestinal pathogens at the point-of-need in < 30 minutes with funding from the NCATS SBIR parent grant TR 001912. We have used the same platform technology we are developing in the parent grant to develop a rapid (<30 minute), low-cost and instrument-free paper strip test for SARS-CoV-2 that can be performed in a wide range of settings. Our tests are more sensitive than the antigen tests since the RNA of the virus are exponentially amplified. The value proposition of this test is that it is fast and readily available to the patient (30 minutes at the doctor's office with a simple, physician's office laboratory vs 2-3 days sending samples to a laboratory) which allows faster isolation and treatment of the patient. Our test will also be valuable in laboratories and hospitals with limited resources in the developed and the developing world that do not have an RT-PCR instrument to test for coronavirus. We propose the commercialization of a simple, rapid, ow-cost and instrument-free test to detect SARS-CoV-2. We will perform the analytical and clinical validation required for the FDA Emergency Use Authorization (EUA). We will also manufacture and commercialize our test.

IC Name
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
  • Activity
    R44
  • Administering IC
    TR
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    597814
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    350
  • Ed Inst. Type
  • Funding ICs
    NCATS:597814\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    GODX, INC.
  • Organization Department
  • Organization DUNS
    078457602
  • Organization City
    MADISON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    537191293
  • Organization District
    UNITED STATES